Key Takeaways
- China has approved NEO, an invasive brain-computer interface device, for commercial medical use.
- The brain chip is designed to help some paralysis patients control a robotic glove through brain signals.
- NEO uses a less invasive placement above the brain’s protective dura layer rather than piercing the cortex.
- The approval gives China an early lead over Neuralink in commercial brain implant availability.
- Experts say BCI technology offers medical promise but also raises safety, privacy and cybersecurity concerns.
China Moves Ahead in Brain-Computer Interface Race
China has taken a major step in the medical technology race by approving the commercial use of a brain-computer interface device designed for patients with paralysis. The device, called NEO, has been developed by Shanghai-based Neuracle Medical Technology, also known as Borui Kang Medical Technology, with research support linked to Tsinghua University. The approval is significant because it moves implantable brain-interface technology from controlled testing toward real-world medical use.
The decision makes China the first country to authorize an invasive brain-computer interface medical device for market use outside clinical trials. For patients with severe movement limitations, the development could offer a new form of assisted independence, especially in basic hand movement and grasping tasks. It also places China in a stronger position in a field where global competition is increasing quickly.
How NEO Helps Paralysis Patients Control Movement
NEO is designed for people living with paralysis caused by cervical spinal cord injuries. These injuries can affect communication between the brain and the body, leaving patients unable to move their hands or arms normally even when the brain still forms the intention to move. The system works by recording brain signals when a patient imagines moving the hand.
Those signals are decoded by an external computer and translated into commands for an assistive robotic glove. In practical terms, the aim is not to fully restore natural hand function immediately, but to help patients perform limited grasping actions such as holding, picking up or handling simple objects. Even small improvements in hand movement can make a meaningful difference for people who depend heavily on caregivers for daily tasks.
The technology is being positioned as a medical support tool rather than a general consumer gadget. This distinction is important because brain-computer interfaces are often discussed in futuristic terms, but the first serious applications are focused on patients with major neurological or mobility challenges.
Less Invasive Design Sets NEO Apart
One of NEO’s most important features is its less invasive design compared with some competing brain implant systems. The coin-sized implant is placed between the skull and the brain, resting on the dura mater, which is the brain’s protective outer layer. It uses eight electrodes to collect movement-related brain signals and sends them to a processing system that converts them into digital instructions.
This approach avoids piercing the cerebral cortex, the outer layer of brain tissue involved in many advanced brain functions. By comparison, Neuralink’s N1 implant uses very thin electrode threads inserted into brain tissue. Both approaches have their own scientific goals and engineering trade-offs, but NEO’s design may appeal to regulators and doctors looking for a balance between signal collection and surgical risk reduction.
However, any implant placed near the brain still carries medical risk. Surgery can involve complications such as infection, bleeding, tissue damage or immune response. Long-term safety also matters because the brain may react to foreign material over time. That is why regular clinical monitoring and strict eligibility rules remain central to the use of such devices.
Approval Puts China Ahead of Neuralink Commercially
The commercial approval of NEO gives China a visible lead over Elon Musk’s Neuralink in terms of market authorization. Neuralink began human trials in 2024 and continues to test its N1 brain implant. Its system has drawn global attention because it allows people with paralysis to control digital devices such as computers using thought-based commands.
However, Neuralink has not yet received broad commercial approval from the US Food and Drug Administration for general market use. China’s move therefore marks a different type of milestone: not only a successful trial or demonstration, but regulatory permission for a medical brain implant to move toward wider patient availability under approved conditions.
Reports from early use of brain-computer interface systems show how emotional and practical these technologies can be for patients. One Neuralink trial participant, Audrey Crews, said on X that she had tried writing her name for the first time in 20 years. Such examples show why researchers, patients and companies see major potential in this field, even as regulators remain cautious.
Medical Promise Comes With Privacy and Safety Risks
Brain-computer interfaces could become one of the most important medical technologies of the coming decades. Researchers are exploring possible uses in movement disorders, stroke recovery, epilepsy, Parkinson’s disease, depression, speech assistance and even vision restoration. For now, however, the clearest near-term use remains medical support for patients with serious paralysis or neurological damage.
The technology also raises sensitive ethical and cybersecurity questions. Brain-computer interface systems collect neural data, which is far more personal than ordinary digital information. If future systems become connected to computers, phones or assistive machines, they will need strong safeguards against unauthorized access, misuse, hacking or manipulation of connected devices.
Questions about who owns neural data, how it is stored, who can access it and how long it can be retained will become more important as brain implants move from research labs into hospitals and commercial medical markets. NEO’s approval shows the direction of travel: the brain-chip industry is no longer only experimental. It is now entering a regulated medical phase where innovation, patient safety, privacy and public trust will have to move together.
